insulin
Pre-clinical- Indications
- Diabetes
Company intelligence / Profile preview
SFC Fluidics has developed a next-generation microfluidic-based patch pump system ("Gemini") designed to deliver both insulin and glucagon for automated diabetes management. The Gemini acts as an "artificial pancreas," aiming to improve glycemic control by automating hormone dosing. The company has ongoing collaborations with Duracell to optimize power systems for their devices. Clinical/commercial launch of the Gemini pod and system in the U.S. market appears imminent but no published clinical trial results are available yet.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SFC Fluidics.